This site is intended for healthcare professionals

NICE rejects Xospata to treat AML with FLT3 mutations- Astellas

Read time: 1 mins
Published:18th Jan 2020
NICE (The National Institute for Health and Care Excellence) has recommended against Xospata (gilteritinib) from Astellas for patients with relapsed/refractory acute myeloid leukemia (AML) who harbor a FLT3 mutation. Xospata costs £14,188 for a 28-day pack and although Astellas had offered a confidential discount to the NHS, uncertainty over long-term survival means the drug did not meet the NICE cost-effectiveness calculations .
Condition: Acute Myelogeous Leukemia (AML)
Type: drug

Learning Zones

The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.